Nuclear survivin expression

A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer

Yao Kuang Wu, Chun Yao Huang, Mei Chen Yang, Chou Chin Lan, Chih Hsin Lee, Err Cheng Chan, Kuei Tien Chen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Survivin, a structurally unique protein expressed in most common human neoplasms, is thought to support cell cycle progression and suppress apoptosis. Survivin expression is highly correlated with advanced non-small cell lung cancer (NSCLC) and poor prognosis. In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. The 48 patients with NSCLC included 32 (66.7%) males and 16 (33.3%) females. Mean age at diagnosis was 59.4 years (range 36-83 years), and median follow-up time was 20.4 months (range 3.4-59.0 months). Patients with high tumor N-survivin expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P <0.001). Adjusted multivariate modeling found high tumor N-survivin expression to be an independent prognostic factor for a clinical response to chemotherapy (high vs. low, OR 6.14, 95% CI 1.62-23.29; P = 0.008). Median overall survival differed significantly between those with high tumor N-survivin expression who did/did not respond to chemotherapy and between those with low tumor N-survivin expression who did/did not respond to chemotherapy (P <0.05). Tumor N-survivin expression shows promise as a predictive biomarker in the chemotherapy setting as a surrogate marker of high proliferation status.

Original languageEnglish
Article number79
JournalMedical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
docetaxel
Biomarkers
taxane
Paclitaxel
Cell Cycle
Retrospective Studies
Apoptosis
Pathology
Survival
Proteins

Keywords

  • Docetaxel
  • Non-small cell lung cancer
  • Paclitaxel
  • Platinum-taxane chemotherapy
  • Survivin expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Nuclear survivin expression : A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer. / Wu, Yao Kuang; Huang, Chun Yao; Yang, Mei Chen; Lan, Chou Chin; Lee, Chih Hsin; Chan, Err Cheng; Chen, Kuei Tien.

In: Medical Oncology, Vol. 31, No. 8, 79, 2014.

Research output: Contribution to journalArticle

Wu, Yao Kuang ; Huang, Chun Yao ; Yang, Mei Chen ; Lan, Chou Chin ; Lee, Chih Hsin ; Chan, Err Cheng ; Chen, Kuei Tien. / Nuclear survivin expression : A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer. In: Medical Oncology. 2014 ; Vol. 31, No. 8.
@article{e206e17b63d747638328274e1942841e,
title = "Nuclear survivin expression: A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer",
abstract = "Survivin, a structurally unique protein expressed in most common human neoplasms, is thought to support cell cycle progression and suppress apoptosis. Survivin expression is highly correlated with advanced non-small cell lung cancer (NSCLC) and poor prognosis. In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. The 48 patients with NSCLC included 32 (66.7{\%}) males and 16 (33.3{\%}) females. Mean age at diagnosis was 59.4 years (range 36-83 years), and median follow-up time was 20.4 months (range 3.4-59.0 months). Patients with high tumor N-survivin expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P <0.001). Adjusted multivariate modeling found high tumor N-survivin expression to be an independent prognostic factor for a clinical response to chemotherapy (high vs. low, OR 6.14, 95{\%} CI 1.62-23.29; P = 0.008). Median overall survival differed significantly between those with high tumor N-survivin expression who did/did not respond to chemotherapy and between those with low tumor N-survivin expression who did/did not respond to chemotherapy (P <0.05). Tumor N-survivin expression shows promise as a predictive biomarker in the chemotherapy setting as a surrogate marker of high proliferation status.",
keywords = "Docetaxel, Non-small cell lung cancer, Paclitaxel, Platinum-taxane chemotherapy, Survivin expression",
author = "Wu, {Yao Kuang} and Huang, {Chun Yao} and Yang, {Mei Chen} and Lan, {Chou Chin} and Lee, {Chih Hsin} and Chan, {Err Cheng} and Chen, {Kuei Tien}",
year = "2014",
doi = "10.1007/s12032-014-0079-4",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "8",

}

TY - JOUR

T1 - Nuclear survivin expression

T2 - A prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer

AU - Wu, Yao Kuang

AU - Huang, Chun Yao

AU - Yang, Mei Chen

AU - Lan, Chou Chin

AU - Lee, Chih Hsin

AU - Chan, Err Cheng

AU - Chen, Kuei Tien

PY - 2014

Y1 - 2014

N2 - Survivin, a structurally unique protein expressed in most common human neoplasms, is thought to support cell cycle progression and suppress apoptosis. Survivin expression is highly correlated with advanced non-small cell lung cancer (NSCLC) and poor prognosis. In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. The 48 patients with NSCLC included 32 (66.7%) males and 16 (33.3%) females. Mean age at diagnosis was 59.4 years (range 36-83 years), and median follow-up time was 20.4 months (range 3.4-59.0 months). Patients with high tumor N-survivin expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P <0.001). Adjusted multivariate modeling found high tumor N-survivin expression to be an independent prognostic factor for a clinical response to chemotherapy (high vs. low, OR 6.14, 95% CI 1.62-23.29; P = 0.008). Median overall survival differed significantly between those with high tumor N-survivin expression who did/did not respond to chemotherapy and between those with low tumor N-survivin expression who did/did not respond to chemotherapy (P <0.05). Tumor N-survivin expression shows promise as a predictive biomarker in the chemotherapy setting as a surrogate marker of high proliferation status.

AB - Survivin, a structurally unique protein expressed in most common human neoplasms, is thought to support cell cycle progression and suppress apoptosis. Survivin expression is highly correlated with advanced non-small cell lung cancer (NSCLC) and poor prognosis. In this retrospective study of banked pathology tissue of patients with advanced NSCLC, we tested for correlations of N-survivin expression in tumor tissues and responsiveness to treatment with platinum-based regimens containing paclitaxel or docetaxel. The 48 patients with NSCLC included 32 (66.7%) males and 16 (33.3%) females. Mean age at diagnosis was 59.4 years (range 36-83 years), and median follow-up time was 20.4 months (range 3.4-59.0 months). Patients with high tumor N-survivin expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P <0.001). Adjusted multivariate modeling found high tumor N-survivin expression to be an independent prognostic factor for a clinical response to chemotherapy (high vs. low, OR 6.14, 95% CI 1.62-23.29; P = 0.008). Median overall survival differed significantly between those with high tumor N-survivin expression who did/did not respond to chemotherapy and between those with low tumor N-survivin expression who did/did not respond to chemotherapy (P <0.05). Tumor N-survivin expression shows promise as a predictive biomarker in the chemotherapy setting as a surrogate marker of high proliferation status.

KW - Docetaxel

KW - Non-small cell lung cancer

KW - Paclitaxel

KW - Platinum-taxane chemotherapy

KW - Survivin expression

UR - http://www.scopus.com/inward/record.url?scp=84902937777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902937777&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0079-4

DO - 10.1007/s12032-014-0079-4

M3 - Article

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 8

M1 - 79

ER -